
Lidija Bach-Rojecky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9374516/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience, 2011, 186, 201-207.	1.1	176
2	Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 2019, 11, 459.	1.5	123
3	Central origin of the antinociceptive action of botulinum toxin type A. Pharmacology Biochemistry and Behavior, 2009, 94, 234-238.	1.3	122
4	Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. European Journal of Pharmacology, 2010, 633, 10-14.	1.7	108
5	Central Action of Peripherally Applied Botulinum Toxin Type A on Pain and Dural Protein Extravasation in Rat Model of Trigeminal Neuropathy. PLoS ONE, 2012, 7, e29803.	1.1	89
6	Botulinum toxin type A in experimental neuropathic pain. Journal of Neural Transmission, 2005, 112, 215-219.	1.4	81
7	Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croatian Medical Journal, 2005, 46, 201-8.	0.2	60
8	Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology, 2013, 70, 331-337.	2.0	52
9	Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics, 2020, 21, 141-156.	0.6	39
10	Lack of antiâ€inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundamental and Clinical Pharmacology, 2008, 22, 503-509.	1.0	37
11	Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. Journal of Neural Transmission, 2014, 121, 665-669.	1.4	37
12	Reduced Brain Antioxidant Capacity in Rat Models of Betacytotoxic-Induced Experimental Sporadic Alzheimer's Disease and Diabetes Mellitus. Neurochemical Research, 2007, 32, 1709-1717.	1.6	36
13	Role of central versus peripheral opioid system in antinociceptive and antiâ€inflammatory effect of botulinum toxin type A in trigeminal region. European Journal of Pain, 2018, 22, 583-591.	1.4	28
14	Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain. Journal of Neural Transmission, 2016, 123, 1403-1413.	1.4	20
15	Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. Personalized Medicine, 2019, 16, 171-184.	0.8	18
16	The antidepressant activity of Hypericum perforatum L. measured by two experimental methods on mice. Acta Pharmaceutica, 2004, 54, 157-62.	0.9	16
17	Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundamental and Clinical Pharmacology, 2010, 24, 43-45.	1.0	11
18	Antinociceptive effect of botulinum toxin type A on experimental abdominal pain. European Journal of Pharmacology, 2014, 745, 190-195.	1.7	9

LIDIJA BACH-ROJECKY

#	Article	IF	CITATIONS
19	Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle. Personalized Medicine, 2019, 16, 511-525.	0.8	8
20	What have we learned about antinociceptive effect of botulinum toxin type A from mirror-image pain models?. Toxicon, 2020, 185, 164-173.	0.8	5
21	Resolving Issues About Efficacy and Safety of Low-Dose Codeine in Combination Analgesic Drugs: A Systematic Review. Pain and Therapy, 2020, 9, 171-194.	1.5	5
22	Influence of ethanol on the myorelaxant effect of diazepam in rats. Acta Pharmaceutica, 2005, 55, 115-22.	0.9	4
23	Personalized Anesthetic Pharmacology. , 2021, , 65-92.		3
24	Analgesic effect of caffeine and clomipramine: a possible interaction between adenosine and serotonin systems. Acta Pharmaceutica, 2003, 53, 33-9.	0.9	1
25	Meningeal extravasation, efficacy of botulinum toxin or triptans is not specific for pathophysiology of migraine only. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-2-34.	0.0	0
26	Basic Science of Pain and Botulinum Toxin. , 2020, , 113-129.		0
27	Botulinum toxin type A: Basic pharmacological profile and therapeutic applications. Arhiv Za Farmaciju, 2020, 70, 10-19.	0.2	0